<DOC>
	<DOCNO>NCT01273259</DOCNO>
	<brief_summary>DHEA prevents reverse chronic hypoxic pulmonary hypertension chronic hypoxic-pulmonary hypertension model rat . However , study perform human . The purpose study determine DHEA effective treatment respiratory pulmonary hypertension adult Chronic Obstructive Pulmonary Disease ( COPD ) exercise capacity haemodynamic variable . Patients receive randomisation either 25 mg/day 200mg/day oral DHEA one-year period . Evaluation concern clinical parameter , echocardiography right catheterization treatment . Primary end-point six-minute walk test . This prospective double blind , randomise , placebo control study realize four university hospital France : Bordeaux , Strasbourg , Toulouse Limoges .</brief_summary>
	<brief_title>Study Dehydroepiandrosterone ( DHEA ) Respiratory Pulmonary Hypertension Adults</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Dehydroepiandrosterone</mesh_term>
	<criteria>Age ≥ 18 year old ≤ 75 year old Chronic Obstructive Pulmonary Disease FEVs/VC &lt; 70 % ( * ) Respiratory pulmonary hypertension mean pulmonary arterial pressure ≥ 20 mmHg ( * ) relate normal pulmonary capillar pressure assess catheterization right side heart ( pulmonary capillary wedge pressure ≤12mmHg ) PO2 ≤ 70 mmHg assess arterial gasometry ease If oxygenotherapy oxygenotherapy 6 month prescreening Written informed consent ( * ) Criteria assess last health check last exams COPD diagnosis clinical instability and/or respiratory exacerbation dangerous catheterization Pregnancy ( ßHCG &gt; 20 UI /l ) breastfeed go General corticotherapy &gt; 0,5 mg/kg/day prednisolon equivalent Hepatic insufficiency ( TP &lt; 50 % ) renal insufficiency ( creatininemia &gt; 130 µmol/l ) diabetes mellitus type I II ( treated oral antidiabetic insulin ) Leftheart failure ( coronary heart disease and/or leave valvulopathy ) High level prostatic specific antigen ( PSA ) ( &gt; 7ng/ml ) Cancer antecedent treatment go</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Hypertension , pulmonary</keyword>
	<keyword>DHEA</keyword>
	<keyword>six-minute walk test</keyword>
	<keyword>pulmonary arterial pressure</keyword>
</DOC>